Summary
This 2024 narrative review in Current Diabetes Reports synthesises evidence on mechanistic links between metabolic dysfunction-associated steatotic liver disease (MASLD) and atherosclerosis. The authors propose that shared metabolic pathways—likely involving dyslipidaemia, insulin resistance, and systemic inflammation—underpin the epidemiological association between hepatic steatosis and cardiovascular disease risk in individuals with metabolic dysregulation. The review integrates current understanding of how liver metabolic dysfunction may contribute to atherosclerosis development.
Regional applicability
As a mechanistic review of metabolic disease pathways, the findings are broadly applicable to United Kingdom clinical and public health contexts, where metabolic dysfunction-associated liver disease and atherosclerosis represent significant health burdens. Transferability depends on whether the proposed pathways operate similarly across populations with varying genetic backgrounds and dietary patterns.
Key measures
Mechanistic pathways linking liver metabolic dysfunction to atherosclerosis; dyslipidaemia; insulin resistance; systemic inflammation markers; cardiovascular disease risk
Outcomes reported
The review synthesises evidence on mechanistic links between metabolic dysfunction-associated steatotic liver disease (MASLD) and atherosclerosis risk. It examines shared metabolic pathways including dyslipidaemia, insulin resistance, and systemic inflammation that may connect hepatic steatosis to cardiovascular disease development.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.